Ken Rhodes
About Ken Rhodes
Ken Rhodes is the Vice President of Research, Neuroscience at Bristol Myers Squibb and a small business owner at GaliptyLight, LLC, with over 30 years of experience in neuroscience research and drug discovery.
Current Role at Bristol Myers Squibb
Ken Rhodes currently serves as the Vice President of Research, Neuroscience at Bristol Myers Squibb. Based in Cambridge, Massachusetts, his work focuses on advancing neuroscience research and contributing to the development of new therapies. This role leverages his extensive experience in CNS research, acquired over several decades.
Previous Experience at Pfizer
From 2021 to 2023, Ken Rhodes was Vice President of Rare Neurology & Discovery Biology at Pfizer. During his tenure, he was instrumental in developing therapeutic strategies for rare neurological diseases. His role at Pfizer allowed him to apply his expertise in neurobiology to drive innovative research initiatives.
Leadership at Wave Life Sciences
Ken Rhodes served as Senior Vice President of Therapeutics Discovery at Wave Life Sciences from 2020 to 2021. In this role, he led the Therapeutics Discovery team, focusing on pioneering genetic medicine approaches. His leadership contributed to Wave's mission of developing transformative therapies for genetic diseases.
Scientific Leadership at Yumanity Therapeutics
Between 2014 and 2020, Ken Rhodes was the Chief Scientific Officer at Yumanity Therapeutics. His work was pivotal in the discovery of novel therapeutic targets for neurodegenerative diseases. Under his scientific leadership, Yumanity made significant strides in understanding and tackling these complex conditions.
Founding GaliptyLight, LLC
In addition to his roles in large pharmaceutical companies, Ken Rhodes founded and operates GaliptyLight, LLC, a small business based in Belmont, MA. This venture reflects his entrepreneurial spirit and continuous drive to innovate within and beyond the pharmaceutical industry.
Educational Background in Neuroscience
Ken Rhodes holds a Ph.D. in Anatomy and Neurobiology from Boston University, which he attained from 1986 to 1991. He also earned a BA in Psychology from Williams College, where he studied from 1981 to 1985. His educational background laid a solid foundation for his extensive career in neuroscience research and drug discovery.